FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy